Latest news
Ironwood Pharmaceuticals’ Earnings Call Highlights LINZESS Surge - TipRanksTipRanks · Fri, 07 Aug 2026 04:30:00 GMTIronwood Pharmaceuticals Inc (IRWD) (Q2 2026) Earnings Call Highlights: Strong LINZESS Growth ... - Yahoo FinanceYahoo Finance · Thu, 06 Aug 2026 23:16:59 GMTIRWD: Strong revenue and profit growth fueled by LINZESS, with key pipeline and financial milestones achieved - TradingViewTradingView · Thu, 06 Aug 2026 20:09:18 GMTIronwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results - BioSpaceBioSpace · Thu, 06 Aug 2026 12:39:15 GMTIRWD: Q2 2026 net sales surged 44% year-over-year, prompting raised full-year guidance - TradingViewTradingView · Thu, 06 Aug 2026 12:31:44 GMTIRWD: Raised 2026 guidance after robust Q2 LINZESS sales, margin gains, and debt repayment - TradingViewTradingView · Thu, 06 Aug 2026 12:28:28 GMTIronwood Raises 2026 Guidance After Q2: Revenue $113M, GAAP Net Income $51M, Adjusted EBITDA $83M - TradingViewTradingView · Thu, 06 Aug 2026 11:13:01 GMTFDA approves Ironwood's LINZESS for functional constipation in children 2+ - Stock TitanStock Titan · Thu, 06 Aug 2026 11:05:00 GMT